Novo Nordisk
EMEA · SalesNovo Nordisk licensed Nanexa's proprietary PharmaShell long-acting drug-delivery technology platform for use in up to five injectable drugs targeting obesity, type 2 diabetes, and metabolic conditions. This is part of two nearly $4 billion in licensing deals announced in late September 2026.
curated · 2026-10-02 · context →
Novo Nordisk acquiring obesity treatment asset from Hengrui for up to $2.6B, gaining a once-weekly pill to compete with Eli Lilly's Zepbound
curated · 2026-09-29 · context →
Novo Nordisk licenses Nanexa drug technology in a deal valued at up to €1.17 billion
curated · 2026-09-25 · context →
European Commission approved Novo Nordisk's Wegovy® oral pill as the first oral GLP-1 receptor agonist for weight management in the EU, plus a ready-to-use pen for the 7.2 mg injection dose.
curated · 2026-07-15 · context →
Novo Nordisk's investigational zenagamtide (once-weekly GLP-1 receptor agonist) demonstrated significant A1C reductions and up to 14.6% weight loss in Phase 2 study of adults with type 2 diabetes, presented at ADA 2026
curated · 2026-06-05 · context →
